Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast06 study of datopotamab deruxtecan in endocrine-refractory HR-positive, HER2 IHC 0 advanced or metastatic breast cancer
2025-521904-23-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in breast cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Feb 2026; status: authorised.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521904-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521904-23-00.